Guidelines for Lyme borreliosis: treatment

The aim of the clinical practice guideline is to support healthcare professionals in the diagnosis and management of patients with proven or suspected Lyme borreliosis (LB). The guideline provides an evidence-based algorithm for antibiotic therapy in confirmed LB cases and outlines recommendations for complex presentations where the three diagnostic criteria are not fully met, suggesting a possible challenge antibiotic therapy in specialized settings. Updated in accordance with international literature and previous French recommendations (HAS, 2022), the guidelines detail antibiotic selection and treatment duration according to clinical manifestations. Doxycycline remains the first-line treatment in most situations, including for children under eight years and pregnant or breastfeeding women. Treatment duration varies from 10 to 28 days depending on disease presentation: 10 days for isolated erythema migrans, 14 days for multiple erythema migrans or early neuroborreliosis, 21 days for lymphocytoma or late neuroborreliosis, and 28 days for Lyme arthritis or acrodermatitis chronica atrophicans. Longer treatments are not justified. In complex or recurrent cases, referral to a reference center is recommended. The guideline discourages the use of anti-inflammatory drugs in acute LB management and notes that corticosteroids do not worsen Lyme-related peripheral facial palsy. European treatment recommendations remain largely consistent across countries.

Authors

Institutions

Publication Details

Journal
Infectious Diseases Now
Published
2025-11-26
DOI
https://doi.org/10.1016/j.idnow.2025.105204
Primary Topic
Vector-borne infectious diseases
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
article

Guidelines for Lyme borreliosis: treatment

F. Roblot, Kévin Bouiller, Steve Nguala, C. Sobas et al.
Infectious Diseases Now
Vector-borne infectious diseases
article

Guidelines for Lyme borreliosis: treatment

F. Roblot, Kévin Bouiller, Steve Nguala, C. Sobas, Yves Hansmann, C. Lenormand, Pedro Arias, A. Raffetin, Elisabeth Baux, Pierre Tattevin, Hans Yssel, A Gautier
article en

Abstract

The aim of the clinical practice guideline is to support healthcare professionals in the diagnosis and management of patients with proven or suspected Lyme borreliosis (LB). The guideline provides an evidence-based algorithm for antibiotic therapy in confirmed LB cases and outlines recommendations for complex presentations where the three diagnostic criteria are not fully met, suggesting a possible challenge antibiotic therapy in specialized settings. Updated in accordance with international literature and previous French recommendations (HAS, 2022), the guidelines detail antibiotic selection and treatment duration according to clinical manifestations. Doxycycline remains the first-line treatment in most situations, including for children under eight years and pregnant or breastfeeding women. Treatment duration varies from 10 to 28 days depending on disease presentation: 10 days for isolated erythema migrans, 14 days for multiple erythema migrans or early neuroborreliosis, 21 days for lymphocytoma or late neuroborreliosis, and 28 days for Lyme arthritis or acrodermatitis chronica atrophicans. Longer treatments are not justified. In complex or recurrent cases, referral to a reference center is recommended. The guideline discourages the use of anti-inflammatory drugs in acute LB management and notes that corticosteroids do not worsen Lyme-related peripheral facial palsy. European treatment recommendations remain largely consistent across countries.

Infectious Diseases NowVol. 55(8)
Centre National de la Recherche Scientifique (FR), Inserm (FR), Université Paris-Est Créteil (FR), Université de Poitiers (FR), Sorbonne Université (FR), Centre Hospitalier Universitaire de Besançon (FR), Institut de Virologie (FR), Santé Publique France (FR), Centre Hospitalier Régional et Universitaire de Nancy (FR), Hospices Civils de Lyon (FR), Dynamique des Génomes et Adaptation Microbienne (FR), Laboratoire Chrono-Environnement (FR), Unité de Recherche sur les Maladies Infectieuses et Tropicales Emergentes (FR), Centre Hospitalier Universitaire de Poitiers (FR), Centre of Ticks and Tick-borne diseases (MW), Pitié-Salpêtrière Hospital (FR), Centre d'Immunologie et des Maladies Infectieuses (FR), Autorité de Sûreté Nucléaire (FR), Centre Hospitalier Intercommunal de Villeneuve-Saint-Georges (FR), Centre Hospitalier Universitaire de Rennes (FR), Hôpital Civil, Strasbourg (FR), Bacterial RNAs & Medicine (FR), Pathogens Host Arthropod Vectors Interfaces (FR), Université de Strasbourg (FR)
Openalex Percentile: Top 61%
Vector-borne infectious diseases
DOIOpen Access PDFOpenAlex
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.